North America Bloodstream Infection Testing Market Report: Market Size & Forecast 2026

Bloodstream infection testing encompasses diagnostic procedures used to detect and identify pathogenic microorganisms circulating in a patient's blood, with sepsis being the most critical condition addressed. The market covers a range of technologies including traditional blood culture systems, molecular assays (PCR-based), and emerging next-generation sequencing methods. In North America, the market benefits from a mature healthcare infrastructure, widespread adoption of advanced diagnostic technologies, and strong regulatory frameworks governing in vitro diagnostics.

• •Market valued at approximately $0.86 billion in 2025 with a projected CAGR of 4.91% through the early 2030s
• •Blood culture methods remain the clinical gold standard, though molecular diagnostics are gaining rapid adoption for their speed and accuracy
• •Hospitals and clinical laboratories constitute the primary end-users, with point-of-care testing emerging as a growth segment

The increasing prevalence of sepsis and other severe bloodstream infections across North America is a primary catalyst for market expansion, with sepsis remaining a leading cause of mortality in hospital settings. An aging population across the United States and Canada is contributing to a higher incidence of immunocompromised and high-risk patient groups requiring frequent BSI testing. The global rise in antimicrobial resistance has intensified the need for rapid, accurate diagnostics to guide targeted antibiotic therapy and reduce inappropriate antimicrobial use.

• •Rising prevalence of hospital-acquired and community-acquired infections, particularly among aging and immunocompromised populations
• •Growing emphasis on antimicrobial stewardship programs, which rely heavily on rapid diagnostic testing to reduce antibiotic misuse
• •Increasing healthcare spending and favorable reimbursement environments in the United States supporting adoption of advanced diagnostic technologies

The North American market is typically segmented by product into instruments, reagents and consumables, and software or data management solutions, with reagents and consumables accounting for the largest share due to the recurring nature of testing. By technology, the market includes culture-based methods, molecular diagnostics, immunoassays, and microscopy, with molecular technologies showing the fastest growth trajectory. The United States represents the dominant share of the regional market, driven by its advanced healthcare infrastructure, high disease burden, and significant R&D investment, while Canada represents a smaller but steadily growing segment.

• •The U.S. commands the majority of the North American BSI testing market due to superior healthcare infrastructure and higher spending on diagnostics
• •Reagents and consumables form the largest product segment, supported by the high-volume, repeat-purchase nature of diagnostic testing
• •Molecular diagnostic technologies, including PCR and isothermal amplification, are the fastest-growing technology segment in the region

What are the recent trends and outlook?

The market is witnessing a meaningful shift toward rapid molecular and syndromic diagnostic panels that can identify pathogens directly from blood samples within hours rather than days, dramatically improving clinical decision-making and patient outcomes. Artificial intelligence and machine learning applications are being integrated into diagnostic workflows to enhance pathogen identification accuracy and predict antimicrobial susceptibility profiles. Over the forecast horizon, the market is expected to benefit from continued technological innovation, growing awareness of sepsis management protocols, and expanding access to advanced diagnostics across smaller hospitals and community care settings.

• •Rapid adoption of syndromic molecular panels and direct-from-blood PCR assays is accelerating, with the potential to supplant traditional culture methods in certain clinical workflows
• •Integration of AI-driven diagnostic interpretation and antimicrobial resistance prediction tools is emerging as a key differentiator among market players
• •The market's long-term trajectory remains positive, underpinned by rising healthcare-associated infection surveillance requirements and ongoing public health investments in diagnostic infrastructure